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Background. Identification and management of risk factors for stroke following isolated coronary artery bypass grafting (CABG)
could potentially lower the risk of such seriousmorbidity.Methods. We retrieved data for 30-day stroke incidence and perioperative
variables for patients undergoing isolated CABG and used multivariate logistic regression to assess the adjusted effect of
preoperative hematocrit concentration on stroke incidence. Results. In 2,313 patients (mean age 65.9 years, 73.6% men), 43 (1.9%,
95% CI: 1.4–2.5) developed stroke within 30 days following CABG (74.4% within 6 days). After adjustment for a priori defined
potential confounders, each 1% drop in preoperative hematocrit concentrationwas associatedwith 1.07 (95%CI: 1.01–1.13) increased
odds for stroke (men, OR: 1.08, 95% CI: 1.01–1.16; women, OR: 1.02, 95% CI: 0.91–1.16). The predicted probability of stroke for
descending preoperative hematocrit concentration exceeded 2% for values <37% (<37% for men (adjusted OR: 2.39, 95% CI:
1.08–5.26) and <38% for women (adjusted OR: 2.52, 95% CI: 0.53–11.98), with a steeper probability increase noted in men). The
association between lower preoperative hematocrit concentration and stroke was evident irrespective of intraoperative transfusion
use. Conclusion. Screening and management of patients with low preoperative hematocrit concentration may alter postoperative
stroke risk in patients undergoing isolated CABG.
1. Introduction
Although mortality rates for patients undergoing isolated
coronary-artery bypass grafting (CABG) continue to decline,
postoperative neurologic morbidity remains a concern [1].
The short-term incidence of stroke after isolated CABG is
close to 2%, although reported risks vary depending on
the underlying risk factors of the population under evaluation
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and the adopted definition of stroke [1]. Knowledge of
the mechanisms of the occurrence of stroke in patients
undergoing isolated CABG is limited. It was previously
assumed that strokes are attributed to the use of extracor-
poreal cardiopulmonary bypass. However, several studies
showed similar stroke rates between patients who undergo
off-pump compared with conventional on-pump surgery [2–
10]. Thus, efforts to reduce the incidence of stroke now focus
on identifying other perioperative and patient-related risk
factors. With this background in mind, we used data from
the large, multicenter database of the American College of
Surgeons National Surgical Quality Improvement Program
(ACS NSQIP) to determine the effects of preoperative hema-
tocrit concentration on the incidence of stroke in patients
undergoing isolated CABG.
2. Materials and Methods
2.1. Study Design and Sample. This was a cohort study using
data from the ACS NSQIP database. Details of the ACS
NSQIP (http://www.acsnsqip.org/) have been recently des-
cribed and are summarized as follows [11].
The American College of Surgeons National Surgical Quality
Improvement Program
Aim. The American College of Surgeons National Surgical
Quality Improvement Program (ACS NSQIP) was set up
as a rigorous data collection tool for outcome measure-
ment. The ACS NSQIP collects data on a variety of clinical
variables, including preoperative risk factors, intraoperative
variables, and 30-day postoperative mortality and morbidity
outcomes for patients undergoing major surgical procedures
in both the inpatient and outpatient setting. Using validated
statistical tools that were developed and tested in large
population-based studies, theACSNSQIPprogramgenerates
an expected outcome based on the case complexity mix.
The observed outcomes are then compared to the expected
outcomes to obtain an O/E ratio and indicate performance
of a particular medical center with regards to the national
average. This data is then used to identify areas in need of
quality improvement.
Participants. Contribution to the ACS NSQIP is on a vol-
untary basis. Nonveterans hospitals that are interested in
quality assurance and outcomes measurement sign-up for
inclusion into the ACS NSQIP database and enter cases
prospectively into this database. There are currently 289 out
of 440 participating sites that are importing data to the ACS
NSQIP database, located in 42 states across the US (272 sites),
three Canadian provinces (15 sites), Lebanon (1 site) and the
UAE (1 site). 52% of the enrolledmedical centers are classified
as academic/teaching and 48% are nonteaching sites. 45% of
participating medical centers have ≥500 beds, 41% have 300–
499 beds, 11% have 100–299 beds, and 3% have <100 beds.
Inclusion/Exclusion of Cases. The ACS NSQIP includes all
major surgeries as determined by CPT codes. The ACS
NSQIP has developed a comprehensive Current Procedural
Terminology (CPT) Code Inclusion List available on the
website (http://www.acsnsqip.org/). Excluded cases are the
following.
(i) Patients under the age of 16 years (data collected after
the year 2008 was for patients over 18 years).
(ii) Cases listed on the CPT Code Exclusion List on the
website (http://www.acsnsqip.org/).
(iii) Trauma cases—specifically: a patient who is admitted
to the hospital with acute trauma and has surgery(s)
for that trauma will be excluded. Any operation
performed after the patient has been discharged from
the trauma stay will be included.
(iv) Transplant cases—specifically: a patientwho is admit-
ted to the hospital for a transplant and has a transplant
procedure and any additional surgical procedure
during the transplant hospitalizationwill be excluded.
Any operation performed after the patient has been
discharged from the transplant stay will be included.
(v) American Society of Anesthesiologists score 6 (brain-
death organ donors).
(vi) Concurrent case—an additional operative procedure
performed by a different surgical teamunder the same
anesthetic (e.g., coronary artery bypass graft proce-
dure on a patient who is also undergoing a carotid
endarterectomy). An assessment is not required on
the concurrent procedure; however, this procedure
would be reported as “concurrent” in the operative
section for the assessed case.
To ensure a diverse surgical case mix, also excluded (at
each center) are the following.
(i) More than 3 inguinal herniorrhaphies in an 8-day
period.
(ii) More than 3 breast lumpectomies in an 8-day period.
(iii) More than 3 laparoscopic cholecystectomies in an 8-
day period.
(iv) If the site is collecting urology cases, more than 3
transurethral resection of the prostate and/or trans-
urethral resection of bladder tumor in an 8-day
period.
It is a validated outcomes registry designed to provide
feedback to member hospitals on 30-day risk-adjusted sur-
gical mortality and morbidity [12, 13]. The database includes
deidentified data on demographics, preoperative risk fac-
tors and laboratory tests, intraoperative conditions and
occurrences, and 30-day postoperative outcomes for adult
patients undergoing major surgery in participating nonvet-
eran’s administration hospitals [12]. Trained surgical clinical
reviewers collect patient data upon admission from the
medical chart, operative log, anesthesia record, interviews
with the surgical attending, and telephone interviewswith the
patient [12]. Data quality is ensured through comprehensive
training of the nurse reviewers, an interrater reliability audit
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of participating sites, regular conference calls, and an annual
meeting [14].
For this study, the available ACS NSQIP participant
use files of the years 2008 (271,368 patients from 211 sites)
and 2009 (336,190 patients from 237 sites) were retrieved
for major surgeries performed within various surgical sub-
specialties at participating ACS NSQIP medical centers in
the US, Canada, Lebanon, and UAE. We identified all iso-
lated primary CABG cases using the Current Procedural
Terminology (CPT) codes: 33510–33514, 33516–33519, 33521–
33523, 33530, and 33533–33536. A total of 2313 patients were
identified and included in this study. In accordance with the
American University of Beirut’s guidelines (which follow the
US Code of Federal Regulations for the Protection of Human
Subjects), institutional review board approval was not needed
or sought for our analysis because data were collected as part
of a quality assurance activity.
2.2. Stroke. The ACS NSQIP registers data on stroke occur-
rence within 30-days of the index operation, which is defined
as a focal brain dysfunction lasting ≥24 hours from a vascular
cause. This definition of stroke encompasses intracranial
hemorrhage, but we considered this outcome as a surrogate
of ischemic stroke because hemorrhagic strokesmake up only
1% of perioperative strokes [15, 16].
2.3. Preoperative Hematocrit Concentration. Retrieved pre-
operative hematocrit concentration reflected the last hemat-
ocrit measurement prior to the index operation. Some 99.9%
of the hematocrit levels were obtained within eight weeks of
the index surgery, 99.1%were obtained within four weeks and
96.6% were obtained within two weeks.
2.4. Statistical Analysis. Descriptive statistics are presented
as means (standard deviation (SD)), medians (interquartile
range (IQR)), or percentages. The primary study outcome
measure was stroke within 30 days of surgery. We used
multivariate logistic regression analysis to retrieve effect
estimates (odds ratios (OR) and 95% confidence intervals
(CI)) upon adjusting the association between preoperative
hematocrit concentration and the outcome of stroke for
potential confounders. Models were built by adjusting (Enter
method) the determinant variable (preoperative hematocrit
concentration) to a priori defined potential confounders
of clinical relevance (risk factors that may cause both
preoperative hematocrit concentration alterations as well as
stroke). Two levels of adjustmentwere used,Model 1 (ORadj-1)
with basic adjustment for the most clinically relevant
variables and Model 2 (ORadj-2) with extended adjustment
for a larger number of clinically relevant risk factors. Data
were near complete, with the exception of missing values for
preoperative hematocrit concentration (𝑛 = 18, 0.7%) and
body mass index (𝑛 = 42, 1.8%) which were imputed by the
respective means of similar sex and age groups.
We carried out the data management and analyses using
the SAS software version 9.1 (SAS Institute Inc., Cary, NC,
USA).
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Figure 1: (a) Number of patients developing stroke on each day in
the 30-day observation period following surgery. (b) Instantaneous
stroke incidence per day in the exposed population.
3. Results
A total of 2,313 patients undergoing isolated CABG were
included in this analysis. The mean age of the study cohort
was 65.9 years (SD: 10.7, range: 25–90) with 1,703 (73.6%)
patients being men. The mean preoperative hematocrit con-
centration was 38.8% (SD: 5.1, range: 12.4–54.9). Forty-three
patients developed stroke within 30 days following CABG,
corresponding to a 30-day cumulative incidence of 1.9% (95%
CI: 1.4–2.5).Themedian time to development of stroke was 4
days (IQR: 1–7 days, min: same day, max: 29 days), with most
patients (74.4%, 95% CI: 59.7–85.0) developing stroke within
the first 6 days after surgery (Figure 1). Characteristics of
patients who developed and those who did not develop stroke
are summarized inTable 1. Patientswhodeveloped stroke had
a lower mean preoperative hematocrit concentration than
those who did not (36.3% versus 38.8%, mean difference:
2.6%, 95% CI: 1.1–4.1).
In an unadjusted analysis, each drop of 1% in preoperative
hematocrit concentration (continuous variable) was associ-
ated with a 1.09 increased odds of 30-day postoperative stroke
(95%CI: 1.04–1.15).The effect was steeper andmore certain in
men (OR: 1.11, 95% CI: 1.04–1.18) than women (OR: 1.05, 95%
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Table 1: Patients’ characteristics.
Parameter No stroke
𝑛 = 2270
Stroke
𝑛 = 43
Preoperative hematocrit concentration,
mean (SD) 38.8 (5.1) 36.3 (4.9)
Age in years, mean (SD) 65.9 (10.7) 69.3 (9.2)
Male, 𝑛 (%) 1,673 (73.7) 30 (69.8)
White race, 𝑛 (%) 1,866 (82.2) 37 (86.0)
Body mass index ≥ 30 kg/m2, 𝑛 (%) 974 (42.9) 15 (34.9)
Diabetes, 𝑛 (%) 831 (36.6) 19 (44.2)
Hypertension, 𝑛 (%) 1,914 (84.3) 39 (90.7)
Congestive heart failure, 𝑛 (%) 255 (11.2) 8 (18.6)
Peripheral vascular disease, 𝑛 (%) 119 (5.2) 2 (4.7)
Currently on dialysis, 𝑛 (%) 56 (2.5) 4 (9.3)
Current Smoker, 𝑛 (%) 554 (24.2) 15 (34.9)
Chronic obstructive pulmonary disease,
𝑛 (%) 237 (10.4) 9 (20.9)
History of transient ischemic attack,
𝑛 (%) 138 (6.1) 4 (9.3)
History of stroke with neurologic
deficit, 𝑛 (%) 100 (4.4) 4 (9.3)
History of stroke without neurologic
deficit, 𝑛 (%) 91 (4.0) 1 (2.3)
Bleeding disorder, 𝑛 (%) 366 (16.1) 8 (18.6)
Disseminated cancer, 𝑛 (%) 3 (0.1) 0 (0.0)
Tumor involving central nervous
system, 𝑛 (%) 1 (0.0) 0 (0.0)
CI: 0.93–1.17). After adjustment for potential confounders,
the effect estimates dropped minimally (ORadj-2 1.07, 95%
CI: 1.01–1.13; men, ORadj-2: 1.08, 95% CI: 1.01–1.16; women,
ORadj-2: 1.02, 95% CI: 0.91–1.16) (Table 2).
The predicted probability of stroke for descending pre-
operative hematocrit concentration values in a clinically rel-
evant range is illustrated in Figure 2(a). The predicted
probability of stroke exceeded 2% (cumulative incidence in
this study and incidence commonly reported in previous
studies) for preoperative hematocrit concentration values
<37% (Figure 2(a)). Upon stratification for men and women,
the threshold was <37% for men and <38% for women,
with a steeper probability increase noted in men beyond
the threshold (Figure 2(b)). The adjusted increase in odds
of stroke (ORadj-2) for men with a preoperative hematocrit
concentration <37% compared with ≥37% was 2.39 (95%
CI: 1.08–5.26), while the adjusted increase in odds of stroke
(ORadj-2) for women with a preoperative hematocrit concen-
tration <38% compared with ≥38% was 2.52 (95% CI: 0.53–
11.98) (Table 2).
A total of 1,779 (76.9%, 95% CI: 75.2–78.6) patients
received intraoperative transfusions (55.1% received 1 or 2
packed red blood cell (pRBC) units and 21.8% received 3
or more pRBC units). The odds of 30-day stroke were more
notably increased in patients receiving 3 or more pRBC units
(OR: 2.69, 95% CI: 1.04–7.00) than patients receiving 1 or 2
pRBC units (OR: 1.55, 95% CI: 0.62–3.84) when compared to
0
1
2
3
4
5
6
7
8
9
10
1820222426283032343638404244464850
Preoperative hematocrit concentration (%)
Pr
ob
ab
ili
ty
 o
f s
tro
ke
 (%
)
(a)
0
1
2
3
4
5
6
7
8
9
10
11
12
13
1820222426283032343638404244464850
Pr
ob
ab
ili
ty
 o
f s
tro
ke
 (%
)
Preoperative hematocrit concentration (%)
Men
Women
(b)
Figure 2: Predicted probability of 30-day postoperative stroke as a
function of preoperative hematocrit concentration in (a) all patients
and (b) men and women.
patients who did not receive intraoperative transfusions. The
mean preoperative hematocrit concentration was lower in
patients who received 3 or more pRBC units intraoperatively
than those who did not (36.1% versus 39.5%,mean difference:
3.4%, 95% CI: 2.9–3.9) (Figure 3(a)). The odds of receiving 3
or more pRBC intraoperatively were 1.14 (95% CI: 1.12–1.17)
for each 1% drop in preoperative hematocrit concentration
(Figure 3(b)).
The association between preoperative hematocrit con-
centration (continuous variable) and 30-day postoperative
stroke was observed in both patients who received (ORadj-2:
1.10, 95% CI: 1.02–1.18) and those who did not receive
(ORadj-2: 1.04, 95% CI: 1.01–1.08) 3 or more pRBC units
intraoperatively, althoughwith higher effect noted in patients
who received intraoperative transfusions. This indicated that
the effects of preoperative hematocrit concentration on 30-
day postoperative stroke are not solely mediated by the use of
3 or more intraoperative pRBC transfusions.
4. Discussion
The incidence of stroke in our study, relying on data from
isolated CABG procedures performed in 2008 and 2009,
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Table 2: Effects of preoperative hematocrit concentration on 30-day postoperative stroke.
Variable
Odds of stroke
ORunadj (95% CI) ORadj-1 (95% CI) ORadj-2 (95% CI)
Preoperative hematocrit concentration
(continuous variable, per 1% decrease)
All patients (𝑛 = 2,313) 1.09 (1.04–1.15) 1.09 (1.03–1.15) 1.07 (1.01–1.13)
Men (𝑛 = 1,703) 1.11 (1.04–1.18) 1.10 (1.04–1.17) 1.08 (1.01–1.16)
Women (𝑛 = 610) 1.05 (0.93–1.17) 1.04 (0.92–1.17) 1.02 (0.91–1.16)
Preoperative hematocrit concentration
(categorized)
All patients <37% versus ≥37% 1.92 (1.05–3.51) 1.76 (0.93–3.35) 1.49 (0.76–2.91)
Men <37% versus ≥37% 3.07 (1.49–6.34) 2.80 (1.34–5.88) 2.39 (1.08–5.26)
Women <38% versus ≥38% 2.88 (0.63–13.10) 2.71 (0.59–12.42) 2.52 (0.53–11.98)
ORunadj : Unadjusted odds ratio.
ORadj-1 : Adjusted odds ratio according to Model 1. Adjusted for age, sex, and race.
ORadj-2: Adjusted odds ratio according to Model 2. Adjusted for all variables in Table 1.
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Figure 3: (a) Bar chart showing mean preoperative hematocrit
concentration according to the number of pRBC units transfused
intraoperatively, whiskers present standard deviation. (b) Predicted
probability of receiving 3 or more pRBC units intraoperatively as a
function of preoperative hematocrit concentration. pRBC = packed
red blood cell.
was 1.9%, which is in close agreement to recent reports
[17]. It should be noted, however, that estimated rates are
much higher when asymptomatic infarcts are included in
the definition of stroke. In addition, strokes may be missed
in the perioperative period, since patients are often receiv-
ing pain medications or sedatives, which can mask subtle
neurologic signs [1]. The study by Tarakji and colleagues
reported an intraoperative occurrence in 40% of overall
stroke cases (a total of 705 patients developed stroke among
45432 participants in the study) [17]. None of the 43 cases
in this report had stroke documentation intraoperatively,
although 5 (11.6%) developed stroke on the same day of
surgery. However, the distribution of stroke risk per day in
the postoperative period in our study matches that reported
by Tarakji and colleagues [17], with a peak incidence during
the first 6 days following surgery followed by a decline in
risk.
We identified an association between descending pre-
operative hematocrit concentration values and an increased
risk of stroke in the 30-day period following isolated CABG.
The increased risk of stroke exceeded 2% in patients with
a preoperative hematocrit concentration <37%. Moreover,
the increased postoperative stroke risk attributed to declin-
ing preoperative hematocrit concentration values was more
notable in men than women and was independent of yet
augmented by the excessive use of intraoperative pRBC
transfusions.
Although numerous studies identified the effects of peri-
operative hematocrit alterations and pRBC transfusions on
morbidity and mortality in cardiac surgery, very few reports
evaluated the outcome of stroke in specific. An association
between hemodilutional anemia during cardiopulmonary
bypass (nadir intraoperative hematocrit levels) and the inci-
dence of stroke was previously demonstrated [18, 19]. One
study by Kulier and colleagues showed that both low pre-
operative hemoglobin (<11.0 g/dl) and intraoperative trans-
fusion requirement are predictors of postoperative adverse
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noncardiac outcomes (a composite end point of neurological
and renal events) in patients undergoing CABG [20]. Amore
recent study showed that preoperative hemoglobin <12.5 g/dl
in both men and women is associated with increased
odds of the composite outcome of death, stroke, or acute
kidney injury in cardiac surgery patients, irrespective of
intraoperative pRBC transfusion use; however, there was no
association with the outcome of stroke alone [21]. In this
study, we echo these findings and confirm the independent
contribution of low preoperative hematocrit concentration
on stroke incidence, although a more prominent effect is
observed in patients who require intraoperative transfusions
of 3 or more pRBC units.
Previous studies suggest that intraoperative hypotension
and subsequent hypoperfusionmay be a source of neurologic
injury in patients undergoing CABG [1, 22, 23]. Preoperative
low hematocrit concentration and significant intraoperative
blood loss necessitating excessive transfusion [24, 25] may
both lead to a state of cerebral hypoperfusion; which in
the coexistence of other risk factors (vessel atherosclerosis)
may lead to adverse cerebral events. Of note, patients with
chronic hypertension may be exposed to relative intraop-
erative hypotension to the brain if their blood pressure is
maintained at a normal or slightly low level during surgery,
thus placing them at risk for a watershed stroke [26, 27]. The
use of intraoperative transfusions also leads to immunemod-
ulation. Transfusions may lead to immune activation and
induce multiple organ failure, despite leukoreduction [28].
In fact, systemic inflammation has been associated with
neurologic injury in patients undergoing CABG [1, 22].
Moreover, storage-related posttransfusion hemolysis produc-
ing hemoglobin-driven pathophysiology and thrombogenic
RBC microparticles in stored blood can lead to target organ
damage [29–32]. Thus, our findings support recommenda-
tions of a conservative approach to intraoperative blood use
in patients undergoing isolated CABG [33] and should lead
to a careful consideration of appropriate interventions aimed
at correcting preoperatively low hematocrit levels.
Our study carries several limitations. The ACS NSQIP
database does not record intraoperative nadir hematocrit
or immediate postoperative hematocrit. Thus, we could not
evaluate the association between these variables and a stroke
outcome. Moreover, the database does not record data on
cardiovascular drug use. The ACS NSQIP database also does
not document themeans by which stroke was diagnosed.The
use of magnetic resonance imaging rather than computed
tomographymay result in higher rates of radiographic infarct.
Although the types of imaging techniques used may have
affected the observed incidence of stroke in our study, an
association between the use of a certain imaging technique
and the evaluated risk factors is less likely. Another potential
limitation of this study was that we were unable to control for
hospital effects owing to the absence of hospital identifiers
in our data. There may have been variability in hospital
quality or variability in surgical strategy which may have
potentially confounded the association between risk factors
and outcome. Finally, the possibility of residual confounding
is always present in observational studies.
5. Conclusions
Current efforts continue to focus on reducing the embolic
burden during CABG, being considered as the primary
mechanism through which neurologic injury occurs. Our
study shows that other mechanisms of injury could be
involved. An increasing number of surgical centers now
use preoperative screening to identify patients who have an
increased risk for stroke, and to modify surgical conditions
according to the results of such screening. This approach
should ideally become standard of care.
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